Opinion
Video
Author(s):
Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.